International Trade Bulletin - Volume 1, Issue 1
Client Alert | 2 min read | 03.20.06
Inside this issue:
- CHINA IN THE SPOTLIGHT
- EUROPE IN THE SPOTLIGHT
- DUTY RECOVERY : Many importers and manufacturers pay unnecessary duty on imported merchandise, either directly or as a cost of procured materials
- BILATERAL TRADE: The proposed U.S. – Korea FTA will be the most commercially significant FTA the U.S. has negotiated since NAFTA
- FOREIGN INVESTMENTS: New Indian investment rules allow foreign retailers to set up majority-owned stores in India – a high-growth market eyed by foreign retailers for years
- AIR TRANSPORT: Controversial U.S. DOT proposal to attract investment in the U.S. Airlines draws fire from both sides of the pond rather than hope for Open Skies
- SANCTIONS: The Office of Foreign Assets Control (“OFAC”) of the U.S. Department of the Treasury has issued an interim final rule outlining a new set of enforcement procedures
- NAFTA: NAFTA provisions on “regional value content” (RVC) calculation causes serious problems for related parties
- DUTY SUSPENSION: The Miscellaneous Tariff Bill (MTB) may be more relevant to your business than it sounds - at least if you are an importer of products that American factories do not produce domestically
- INTERNATIONAL IP PROTECTION: Elements of India’s new patent law which took effect in 2005 have prevented Novartis from obtaining a patent for its cancer drug “Gleevec”
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
